A Study of CD19 t-haNK and NAI With Rituximab for Indolent Non-Hodgkin Lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs for people with a slow-growing form of non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see if this new combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of slow-growing B-cell non-Hodgkin lymphoma (such as follicular lymphoma, Waldenstrom macroglobulinemia, or marginal zone lymphoma) that has returned or not responded after at least 2 prior chemotherapy treatments.
- You have previously received rituximab or a similar antibody treatment.
- Your disease is measurable (tumor size at least 15 mm in lymph nodes or 10 mm in organs, or confirmed in bone marrow).
- You are in reasonably good health (able to carry out daily activities) and have adequate organ function (blood counts, liver and kidney function within required limits).
- You agree to use effective birth control during and for 12 months after the study (if you could become pregnant or father a child).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This Phase 1 study tests an investigational treatment for adults with lymphoma that has come back or did not respond to prior treatments. It targets lymphoma cells that have CD19 and CD20 markers, aiming to reduce or control the disease in people with limited options.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
Hear when a new Relapsed B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.